Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma

Therapeutic options for treating advanced melanoma have progressed rapidly in recent decades. Until 6 years ago, the regimen for treating advanced melanoma consisted mainly of cytotoxic agents such as dacarbazine and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have...

Full description

Bibliographic Details
Main Authors:	Taku Fujimura, Yusuke Muto, Yoshihide Asano
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Series:	International Journal of Molecular Sciences
Subjects:	immune checkpoint inhibitors advanced melanoma anti-PD1 Abs anti-CTLA4 Abs efficacy irAEs
Online Access:	https://www.mdpi.com/1422-0067/23/24/15720

Similar Items

A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab
by: Philip Friedlander, et al.
Published: (2018-09-01)

Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma
by: Vasiliki Nikolaou, et al.
Published: (2023-03-01)

Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine
by: Elisa Longhitano, et al.
Published: (2023-03-01)

The use of immunotherapy in the treatment of melanoma
by: Tala Achkar, et al.
Published: (2017-04-01)

Case report: Hashimoto’s thyroiditis after CD19 chimeric antigen receptor T-cell therapy
by: Panpan Chen, et al.
Published: (2022-10-01)

Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations
by: Silvia Casagrande, et al.
Published: (2024-04-01)

Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments
by: Cinzia Vetrei, et al.
Published: (2021-06-01)

Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases
by: Yusuke Muto, et al.
Published: (2022-08-01)

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
by: Biagio Ricciuti, MD, et al.
Published: (2020-11-01)

Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review
by: Alice Indini, et al.
Published: (2021-03-01)

Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial
by: Lærke K. Tolstrup, et al.
Published: (2022-01-01)

The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
by: Chiao-En Wu, et al.
Published: (2020-10-01)

Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%
by: Yutaka Takahara, et al.
Published: (2023-09-01)

Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy
by: David Dora, et al.
Published: (2023-02-01)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
by: Xueyan Wang, et al.
Published: (2022-10-01)

Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment
by: Almog Shalit, et al.
Published: (2023-01-01)

Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease
by: Alf Spitschak, et al.
Published: (2022-12-01)

Immune Checkpoint Inhibitors and Lupus Erythematosus
by: Hans Vitzthum von Eckstaedt, et al.
Published: (2024-02-01)

Tissue‐specific tumor microenvironments influence responses to immunotherapies
by: Amanda J Oliver, et al.
Published: (2019-01-01)

Fever of unknown origin associated with immune checkpoint inhibitors
by: Xu Tong, et al.
Published: (2024-03-01)

Peripheral lymphocyte fluctuation as an indicator of severe immune‐related adverse events in patients treated with immune checkpoint inhibitors
by: Masafumi Haraguchi, et al.
Published: (2023-05-01)

The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma—two sides of the same coin?
by: Robin Reschke, et al.
Published: (2024-03-01)

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
by: Raju Vaddepally, et al.
Published: (2022-03-01)

Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience
by: Martina Merli, et al.
Published: (2023-07-01)

HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment
by: Sophia Gandarillas, et al.
Published: (2024-01-01)

SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color
by: A.B. Pierre, et al.
Published: (2023-12-01)

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)
by: Paolo A. Ascierto, et al.
Published: (2022-09-01)

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy)
by: Paolo A. Ascierto, et al.
Published: (2021-06-01)

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy)
by: Paolo A. Ascierto, et al.
Published: (2023-07-01)

Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)
by: Paolo A. Ascierto, et al.
Published: (2020-09-01)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
by: Muhammad Zubair Afzal, et al.
Published: (2018-07-01)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
by: Ji Li, et al.
Published: (2022-05-01)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
by: Ronen Stoff, et al.
Published: (2022-11-01)

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)
by: Paolo A. Ascierto, et al.
Published: (2019-07-01)

Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade
by: Shuming Chen, et al.
Published: (2024-03-01)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
by: Alicia Quilez, MD, et al.
Published: (2020-03-01)

The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020
by: Paolo A. Ascierto, et al.
Published: (2021-04-01)

Editorial: Decoding checkpoint inhibitor-induced endocrinopathies
by: Deborah L. Burnett, et al.
Published: (2022-07-01)

Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report
by: Tanja Fetter, et al.
Published: (2024-03-01)

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
by: Duaa O. Khair, et al.
Published: (2019-03-01)